Skip to main content
Clinical Trials/NCT02421900
NCT02421900
Unknown
Not Applicable

Analysis of the Role of T-cell Response in Patients With Atrial Fibrillation for Clinical Application

Yonsei University1 site in 1 country100 target enrollmentApril 1, 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Atrial Fibrillation
Sponsor
Yonsei University
Enrollment
100
Locations
1
Primary Endpoint
The frequency (%) of specific marker-expressing cells among CD4 or CD8 T-subsets
Last Updated
7 years ago

Overview

Brief Summary

The purpose of this study is 1) to characterize T-cell response in patients with atrial fibrillation, and 2) to analyze the changes of T-cell response after radio-frequency catheter ablation of atrial fibrillation. First, immune-phenotyping and cytokine profiling of T cells from patients with atrial fibrillation will performed. Next the difference of T-cell immunity among various type of atrial fibrillation patients will be analyzed. Finally the changes of T-cell response and cytokines after radio-frequency catheter ablation of atrial fibrillation will be assessed.

Registry
clinicaltrials.gov
Start Date
April 1, 2015
End Date
March 2020
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients who consent with study
  • patients with age more than19
  • patients who undergoing catheter ablation of atrial fibrillation due to symptomatic, drug refractory atrial fibrillation

Exclusion Criteria

  • Patients who do not agree with study inclusion
  • Permanent AF refractory to electrical cardioversion
  • AF with rheumatic valvular disease
  • Patients with left atrial diameter greater than 60mm
  • Patients with age less than 19
  • Patient with malignant tumor and chronic infection disease
  • Patient are given immune inhibitor and steroidal anti-inflammatory drug within 2weeks

Outcomes

Primary Outcomes

The frequency (%) of specific marker-expressing cells among CD4 or CD8 T-subsets

Time Frame: 1 year

* Immunosenescence marker: CD28, CD57 * Activation marker: CD38, HLA-DR * Differentiation marker: CCR7, CD45RA

Secondary Outcomes

  • The frequency (%) of cytokine-secreting cells among CD4 or CD8 T-subsets(1 year)

Study Sites (1)

Loading locations...

Similar Trials